Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 6/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.40 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5172390 | 0.89 | PLK1 (0.74) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| Cyclapolin 9 SCHEMBL5055142 | 0.87 | PLK1 (1.00) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| Cyclapolin 9 SCHEMBL31560145 | 0.87 | PLK1 (1.00) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| Hydroxyamine SCHEMBL6275415 | 0.86 | PLK1 (0.80) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL9488468 | 0.82 | PLK1 (0.61) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5172960 | 0.81 | PLK1 (0.62) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL15253960 | 0.81 | PLK1 (0.69) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL15254120 | 0.80 | PLK1 (0.58) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5170233 | 0.79 | PLK1 (0.69) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5171055 | 0.79 | PLK1 (1.00) | PLK1CYP3A4CYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589967-B1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2007-05-09 | — | — | EP | claimed |
| JP-2006518361-A | — | — | 2006-08-10 | — | — | JP | claimed |
| US-20060040997-A1 | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
| EP-1589967-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2005-11-02 | — | — | EP | claimed |
| WO-2004067000-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2004-08-12 | — | — | WO | claimed |
| EP-1589967-B1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2007-05-09 | — | — | EP | disclosed |
| US-20060040997-A1 | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1589967-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067000-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040997-A1 | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | CBR3, FGFR3, CCNH | PLK1 4291/4885CYP3A4 1540/4885CYP1A2 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.